Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Phase 3 IGIV, 10% in Alzheimer´s Disease

ClinicalTrials.gov ID: NCT01524887

Public ClinicalTrials.gov record NCT01524887. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease

Study identification

NCT ID
NCT01524887
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Baxalta now part of Shire
Industry
Enrollment
508 participants

Conditions and interventions

Interventions

  • Human albumin 0.25% Biological
  • Immune Globulin Intravenous (Human), 10% Solution Biological

Biological

Eligibility (public fields only)

Age range
50 Years to 89 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 22, 2012
Primary completion
Jul 15, 2013
Completion
Jul 15, 2013
Last update posted
May 18, 2021

2012 – 2013

United States locations

U.S. sites
37
U.S. states
19
U.S. cities
37
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Phoenix Arizona
Not listed Long Beach California
Not listed San Diego California
Not listed Santa Ana California
Not listed Boca Raton Florida
Not listed Delray Beach Florida
Not listed Edgewater Florida
Not listed Orlando Florida
Not listed Decatur Georgia
Not listed Chicago Illinois
Not listed Springfield Illinois
Not listed Paducah Kentucky
Not listed Saint Paul Minnesota
Not listed Olive Branch Mississippi
Not listed Las Vegas Nevada
Not listed Berlin New Jersey
Not listed Chester New Jersey
Not listed Eatontown New Jersey
Not listed Summit New Jersey
Not listed Toms River New Jersey
Not listed Albany New York
Not listed Brooklyn New York
Not listed Latham New York
Not listed Manhasset New York
Not listed New Hyde Park New York
Not listed Cincinnati Ohio
Not listed Oklahoma City Oklahoma
Not listed Tulsa Oklahoma
Not listed Providence Rhode Island
Not listed Austin Texas
Not listed Dallas Texas
Not listed Houston Texas
Not listed San Antonio Texas
Not listed Bennington Vermont
Not listed Charlottesville Virginia
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01524887, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 18, 2021 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01524887 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →